All News

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron Pharmaceuticals) in the management of chronic spontaneous urticaria (CSU), a condition with limited therapeutic options over the past decade.

Mingyang Song, MBBS, ScD, discusses the link between ultraprocessed foods and cancer risk, emphasizing nutrition's role in prevention.

A new survey highlights how the mental toll of loneliness trickles down to have very real physical consequences for patients with chronic illness.

Improving adherence to antiretroviral therapy (ART) in youth living with HIV requires interventions that target both family dynamics and any underlying mental illness.

K. "Vish" Viswanath, PhD, explores the evolution of health misinformation, its sources, and the role of technology in shaping public understanding.

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the need for equitable treatment strategies.

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa.

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a clear-cut strategy, a new review finds.

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung cancer (ES-SCLC).

With artificial intelligence (AI) capabilities freeing up workers and driving billions in gains, pharmacy may soon see a 75% workload drop.

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

Kimlin Tam Ashing, PhD, of City of Hope National Medical Center, emphasizes the vital role of community engagement in cancer research, enhancing trust and communication between scientists and communities.

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.

Smoking prevalence is projected to decline by 2035, yet health consequences persist due to slower reductions among older adults.

Immediate local flap or skin graft following basal cell carcinoma (BCC) can be considered, a study found.

New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.

Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.

Minimal residual disease (MRD)-guided triple therapy showed promising results for relapsed chronic lymphocytic leukemia (CLL), achieving high rates of undetectable disease and prolonged survival.

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Luis Carvajal-Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.